AstraZeneca 4Q10 4Q Revenues: $8.6 billion (-4%) 4Q Earnings: $1.6 billion (+4%) FY Revenues: $33.3 billion (+1%) FY Earnings: $8.1 billion (+7%) Comments: Pharma sales in the U.S. were down 12% due to generic competition and the absence of H1N1 pandemic vaccine revenues. Crestor sales rose 26% in 4Q10 to $1.6 billion and 24% for FY to $5.7 billion. Seroquel sales were up 9% for the year to $5.3 billion, driven by growth in the XR formulation. Symbicort sales were up 15% for 4Q10 ...